Comparison of Agenus Inc. (AGEN) and ChemoCentryx Inc. (NASDAQ:CCXI)

Agenus Inc. (NASDAQ:AGEN) and ChemoCentryx Inc. (NASDAQ:CCXI), both competing one another are Biotechnology companies. We will contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus Inc. 38.69M 11.79 147.18M -1.40 0.00
ChemoCentryx Inc. 89.84M 6.56 12.47M 0.19 52.02

Demonstrates Agenus Inc. and ChemoCentryx Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Agenus Inc. -380.41% 136.2% -110.7%
ChemoCentryx Inc. 13.88% 32.2% 6.5%

Volatility & Risk

A 2.27 beta means Agenus Inc.’s volatility is 127.00% more than Standard and Poor’s 500’s volatility. ChemoCentryx Inc. on the other hand, has 1.72 beta which makes it 72.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio of Agenus Inc. is 1.2 while its Quick Ratio stands at 1.2. The Current Ratio of rival ChemoCentryx Inc. is 2.9 and its Quick Ratio is has 2.9. ChemoCentryx Inc. is better equipped to clear short and long-term obligations than Agenus Inc.

Analyst Recommendations

Agenus Inc. and ChemoCentryx Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agenus Inc. 0 0 0 0.00
ChemoCentryx Inc. 0 2 2 2.50

ChemoCentryx Inc. on the other hand boasts of a $16.88 average price target and a 44.77% potential upside.

Institutional & Insider Ownership

Agenus Inc. and ChemoCentryx Inc. has shares held by institutional investors as follows: 32.4% and 55.5%. 0.1% are Agenus Inc.’s share held by insiders. Competitively, 4.8% are ChemoCentryx Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agenus Inc. 9.13% 27.05% 32.83% -9.62% -27.35% -19.33%
ChemoCentryx Inc. -0.1% -16.33% -9.75% -15.2% 69.59% 68.74%

For the past year Agenus Inc. had bearish trend while ChemoCentryx Inc. had bullish trend.

Summary

ChemoCentryx Inc. beats on 10 of the 12 factors Agenus Inc.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.